26/01/2025
An session with conducted by Dr. Fowler.
Biopulse operates in the Biotechnology sector, and his main mission is the invention, the design, th
Rome
00144
| Lunedì | 09:00 - 18:00 |
| Martedì | 09:00 - 18:00 |
| Mercoledì | 09:00 - 18:00 |
| Giovedì | 09:00 - 18:00 |
| Venerdì | 09:00 - 18:00 |
Lasciando la tua email puoi essere il primo a sapere quando Biopulse pubblica notizie e promozioni. Il tuo indirizzo email non verrà utilizzato per nessun altro scopo e potrai annullare l'iscrizione in qualsiasi momento.
Invia un messaggio a Biopulse:
Biopulse is an Italian company mainly engaged in the medical transnational research sector. The founders of the company, Dr. Enrico Pierluigi Spugnini and Dr. Alfonso Baldi, are internationally considered to be among the leading experts in veterinary electrochemotherapy ECT and electrogenetherapy EGT, and have widely published in international medical and veterinarian journals.
Biopulse operates in the Biotechnology sector, and his main mission is the invention, the design, the manufacture and the marketing of innovative electromedical and electrotherapeutic instruments. Biopulse has realized the phase of design, construction and industrialization of an electroporation device for veterinary use: Onkodisruptor ®.
Electroporator Onkodisruptor ® must be used for veterinary adjuvant or neadjuvant electrochemotherapy ECT or for electrogenetherapy EGT in companion animals, equine, exotics and laboratory animals. This apparatus must be exclusively used under the supervision of a qualified veterinary doctor.
The device is entirely designed and manufactured in Italy with the highest quality standards. The instrument conforms to the following EU Directives (2006/95/EC regarding low voltage safety and related standard).